0%
Print report
Variant interpretation report

BRCA2 c.918T>C, p.Asp306=

NM_000059.4:c.918T>C NP_000050.3:p.(Asp306=) Synonymous · exon 10 View identifiers
Classification
Likely benign

Variant description:

The BRCA2 NM_000059.4:c.918T>C (NP_000050.3:p.(Asp306=)) synonymous variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be Likely Benign. This variant is considered to be Likely Benign by the VCEP (Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA); ClinVar ID 184704).

Five-step scale from benign to pathogenic. This variant is likely benign. Select a step to read what it means.

Likely benign.A likely benign classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About BRCA2

BRCA2 encodes a DNA repair protein that maintains genome stability by repairing double-strand breaks through homologous recombination and by protecting DNA replication forks. It acts as a tumor suppressor, and inherited loss-of-function changes cause hereditary breast and ovarian cancer syndrome, with elevated lifetime risks of breast, ovarian, prostate, and pancreatic cancers; biallelic changes cause Fanconi anemia complementation group D1. Reduced or altered BRCA2 activity is implicated in multiple tumor types, and PARP inhibitors are an approved treatment for BRCA2-associated ovarian and breast cancers.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen BRCA2 VCEP v1.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 3
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 3
BS1Supporting
BS1 · supporting

Met at Supporting: maximum non-cancer gnomAD FAF was 0.00006461, within the ENIGMA BS1 Supporting interval >0.00002 to <=0.0001.

BP1Strong
BP1 · strong

Met at strong strength: residue 306 is outside domains 10-40 and 2481-3186, with SpliceAI maximum delta 0.006 versus the ≤0.1 threshold.

BP6Supporting
BP6 · supporting

Not applicable: the ENIGMA BRCA2 specification explicitly says BP6 is not to be used.

Recorded classification: Likely benign

Likely Benign: BP1 strong plus BS1 supporting satisfy the ENIGMA BRCA2 VCEP's strong-benign plus supporting-benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
15 / 1,591,562 alleles

gnomAD v4.1: 15 / 1,591,562 alleles. Recorded AF 9.4247e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 2.54946e-05; MAF= 0.00255%, 6/235344 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 0.00016372; MAF= 0.01637%, 5/30540 alleles, homozygotes = 0); grpmax FAF= 6.404e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI score
0.006 maximum delta

Recorded SpliceAI maximum delta score: 0.006. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
ClinVar submissions
9 reported laboratory submissions

7 Likely benign · 1 likely benign · 1 Likely Benign. ClinVar API review status: reviewed by expert panel.

Functional evidence
Statement recorded

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen BRCA2 VCEP v1.2, with the data and sources behind each one.

28 criteria with recorded statuses: 3 met · 3 not met · 9 not assessed · 13 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

The variant is a synonymous exon-10 substitution, c.918T>C (p.Asp306=), with no protein-length change; the three requested consequence/LOF criteria are therefore not applicable under the ENIGMA BRCA2 VCEP rules.

The governing VCEP files were searched for c.918T>C, p.Asp306=, and p.D306=; no direct variant-specific entry was found in the named Specifications, Appendices, Table 4, or Houdayer paper text files.

Among the requested criteria, the VCEP supports BP1_Strong because the synonymous variant is outside the defined BRCA2 functional domains and has SpliceAI maximum delta 0.006; PS1, PM1, PM5, and PP2 are not applicable under the VCEP rules.

PS2 and PM6 are not applicable because the ENIGMA BRCA2 specification explicitly designates both de novo criteria Do not use.

PP1 and BS4 remain not assessed because the only exact-variant report gives a one-family observation without the quantitative segregation or non-segregation likelihood ratios required by the VCEP.

For PS4, the exact variant was observed in one family in PMID:16683254, but no matched controls or case-control counts were reported, so the VCEP case-control threshold cannot be evaluated.

PP4 and BP5 require variant-specific combined multifactorial likelihood ratios; no exact row or combined LR was found in the governing clinical-history and multifactorial reference materials.

PP5 and BP6 are explicitly prohibited by the ENIGMA BRCA2 specification.

PM3 is not assessed because the available single-family report does not provide the VCEP-required Fanconi Anemia phenotype, same-gene pathogenic or likely pathogenic co-occurrence, phase, or PM3 point-bearing data.

BP2 is not applicable because the VCEP explicitly instructs that it is not to be used and applies it only in the context of BS2.

For this synonymous BRCA2 variant, PP3 is evaluated through the VCEP's silent-variant splicing path and is not met because SpliceAI maximum delta is 0.006, below 0.2.

BP4 and BP7 are not applicable because their silent-variant paths require location inside a specified clinically important BRCA2 functional domain, whereas codon 306 is outside both domains.

Population criteria evaluated under ClinGen ENIGMA BRCA2 specification v1.2 using the governing non-cancer gnomAD subsets: BS1 Supporting is met; BA1 and PM2 are not met; BS2 is not assessed because qualifying clinical-cohort evidence is unavailable.

Met · 3

BS1 SupportingVCEPMet at Supporting: maximum non-cancer gnomAD FAF was 0.00006461, within the ENIGMA BS1 Supporting interval >0.00002 to <=0.0001. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 v1.2 BS1 Supporting rule applies when filter allele frequency is above 0.00002 and at or below 0.0001 in the specified non-cancer gnomAD populations. The maximum observed non-cancer FAF is 0.00006461 in gnomAD v2.1 non-cancer exomes, which falls within that interval; the gnomAD v3.1 non-cancer genome result is also below 0.0001. BS1 Supporting is met.

VCEP rule
Filter allele frequency (FAF) is above 0.002% (FAF > 0.00002) and less than or equal to 0.01% (FAF ≤ 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: maximum population FAF 6.460999999999997e-05, based on 6/220854 alleles overall and 5/30208 Admixed American alleles.
  • gnomAD v3.1 non-cancer genomes: AF 6.75904e-06 from 1/147950 alleles, homozygotes 0, with maximum population FAF 0.
  • Specifications_V1.2_2024-11-18.docx, Table 1 BS1: preferred datasets are gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes, assessed using maximum filter allele frequency in non-founder populations.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BP1 StrongVCEPMet at strong strength: residue 306 is outside domains 10-40 and 2481-3186, with SpliceAI maximum delta 0.006 versus the ≤0.1 threshold. Details ▾Hide ▴
Reasoning

The variant is a silent substitution at p.Asp306=, outside the VCEP-defined BRCA2 clinically important domains (PALB2 binding aa 10-40 and DNA binding aa 2481-3186). SpliceAI maximum delta is 0.006, satisfying the VCEP requirement of no splicing predicted (≤0.1). Therefore BP1_Strong applies.

VCEP rule
Apply BP1_Strong for silent substitution, missense or in-frame insertion, deletion or delins variants outside a (potentially) clinically important functional domain AND no splicing predicted (SpliceAI ≤0.1). As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA2 PALB2 binding domain aa 10-40; BRCA2 DNA binding aa 2481-3186.
Evidence considered
  • The case identifies NM_000059.4:c.918T>C as synonymous, NP_000050.3:p.(Asp306=) / p.(D306=); PMID:16683254 reports c.918T>C as a synonymous BRCA2 variant in amplicon 10-1.
  • Residue 306 is outside the VCEP-defined PALB2 binding domain aa 10-40 and DNA binding domain aa 2481-3186.
  • SpliceAI scores are DS_AG 0.001, DS_AL 0.001, DS_DG 0.006, and DS_DL 0.001; maximum delta 0.006 is ≤0.1.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
BP6 SupportingVCEPNot applicable: the ENIGMA BRCA2 specification explicitly says BP6 is not to be used. Details ▾Hide ▴
Reasoning

Expert panel Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) classified as Likely benign.

VCEP rule
Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation ... Do not use
Evidence considered
  • ENIGMA BRCA2 specification BP6 entry: reputable-source benign reports are followed by the explicit instruction Do not use.
  • ClinVar reports this variant as Likely benign with expert-panel review; this is not used to apply BP6 because the VCEP prohibits the criterion.
  • ClinVar expert panel classification
Sources

Not met · 3 · evaluated, threshold not reached

PM2 VCEPNot met: the variant was observed in 6/220854 non-cancer gnomAD v2.1 alleles and 1/147950 v3.1 alleles, rather than being absent. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 v1.2 PM2 Supporting rule requires the variant to be absent from controls in the specified non-cancer gnomAD subsets, with adequate read depth. The variant is present in gnomAD v2.1 non-cancer exomes at 6/220854 alleles (AF 2.716726887446005e-05) and in gnomAD v3.1 non-cancer genomes at 1/147950 alleles (AF 6.75904e-06), with zero homozygotes in both datasets. Because it is not absent from controls, PM2 is not met.

VCEP rule
Absent from controls in an outbred population, from gnomAD v2.1 (non-cancer, exome only subset) and gnomAD v3.1 (non-cancer). Region around the variant must have an average read depth ≥25. See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: 6/220854 alleles, AF 2.716726887446005e-05, homozygotes 0.
  • gnomAD v3.1 non-cancer genomes: 1/147950 alleles, AF 6.75904e-06, homozygotes 0.
  • Appendices_V1.2_2024-11-18.docx, Appendix G: PM2 Supporting is based on control-population frequency observations in gnomAD and requires read depth >25; the available variant records are observed, not absent.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in HUMU-40-1557-s001.xlsx.txt.
Sources
PP3 VCEPNot met: SpliceAI maximum delta 0.006 is below the ENIGMA PP3 threshold of ≥0.2 for predicted splicing in silent variants. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_000059.4:c.918T>C; p.Asp306=). The governing ENIGMA rule permits PP3 for predicted splicing in silent variants and requires SpliceAI ≥0.2. The case-specific SpliceAI maximum delta score is 0.006 (DS_DG 0.006; all other delta scores 0.001), below the VCEP threshold; therefore PP3 is not met. No exact variant entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2: PP3 applies to predicted splicing for silent variants when SpliceAI ≥0.2.
  • SpliceAI Lookup for NM_000059.4:c.918T>C: DS_AG=0.001, DS_AL=0.001, DS_DG=0.006, DS_DL=0.001; maximum delta score=0.006.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1: c.918T>C is reported as a synonymous variant observed in one family, confirming the silent-variant scope.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BA1 VCEPNot met: maximum non-cancer gnomAD filter allele frequency was 0.00006461, below the ENIGMA BA1 threshold of >0.001. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 v1.2 BA1 rule requires filter allele frequency above 0.001 in the specified non-cancer gnomAD populations. The governing non-cancer data show a maximum filter allele frequency of 0.00006461 in gnomAD v2.1 non-cancer exomes and 0 in gnomAD v3.1 non-cancer genomes; both are below 0.001. The variant is therefore not eligible for BA1.

VCEP rule
Filter allele frequency (FAF) is above 0.1% (FAF > 0.001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes: 6/220854 alleles, AF 2.716726887446005e-05, homozygotes 0; maximum population FAF 6.460999999999997e-05.
  • gnomAD v3.1 non-cancer genomes: 1/147950 alleles, AF 6.75904e-06, homozygotes 0; maximum population FAF 0.
  • Specifications_V1.2_2024-11-18.docx, Table 1 BA1: preferred datasets are gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes, with application based on maximum filter allele frequency in a non-founder population.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in HUMU-40-1557-s001.xlsx.txt.
Sources

Not assessed · 9 · no assessment recorded

PS3 VCEPNot assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay establishes a damaging functional effect. Details ▾Hide ▴
Reasoning

PS3 cannot be assessed because the ENIGMA BRCA2 Table 9 curated functional-assay file contains no entry for c.918T>C, p.Asp306=, or p.D306=, and the available exact-variant publication reports only a synonymous observation without a protein-function or combined mRNA/protein assay. The VCEP reserves PS3 for well-established functional studies demonstrating a damaging effect through protein-only or combined mRNA-and-protein assays; the available SpliceAI result is not a functional assay and cannot substitute for that requirement.

VCEP rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect. Apply PS3 for assays measuring effect via protein only OR mRNA and protein combined.
Evidence considered
  • ENIGMA Specifications Table 9, searched by c.918T>C, p.Asp306=, and p.D306=: no matching curated functional-assay row was present.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, and HUMU-40-1557-s001.xlsx were searched under all three variant notations; no variant-specific PS3/BS3 functional result was found.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1, row c.918T4C: synonymous, observed in 1 family, coded B; the paper provides no functional assay result for this variant.
  • The case's SpliceAI result has maximum delta score 0.006, but the VCEP PS3 rule requires functional studies and does not permit a splice predictor to substitute for them.
Still missing
  • No c.918T>C, p.Asp306=, or p.D306= entry found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in HUMU-40-1557-s001.xlsx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • A calibrated protein-only or combined mRNA/protein functional assay with validated controls and variant-specific results is unavailable in the reviewed evidence.
Sources
PS4 VCEPNot assessed: one family observation lacks matched controls, so the required PS4 OR ≥4, p-value ≤0.05, and confidence-interval comparison cannot be calculated. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires a case-control study with p-value ≤0.05, OR ≥4, and a lower confidence interval excluding 2.0. PMID:16683254 reports NM_000059.4:c.918T>C (shown as c.918T4C) in one Dutch cancer-clinic family as a synonymous variant, but provides no unaffected/control count or case-control comparison; therefore an OR and 95% CI cannot be computed and PS4 is not assessed. The literature_pass ai_classified_papers list is empty. The variant was not found in the governing SupplementaryTables_V1.2_2024-11-18.xlsx or HUMU-40-1557-s001.xlsx full-text tables under c.918T>C, p.Asp306=, or p.D306=.

VCEP rule
The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. ... Case-control studies; p-value ≤0.05 and OR ≥4 (lower confidence interval excludes 2.0).
Evidence considered
  • ENIGMA BRCA2 specification PS4 rule: case-control studies require p-value ≤0.05 and OR ≥4, with the lower confidence interval excluding 2.0.
  • PMID:16683254, Table 3, BRCA2 amplicon 10-1: c.918T4C, synonymous, observed in 1 family, classification B; no control group or case-control counts are reported.
  • The required case-control metric was not computed because the cited report supplies no control count; no qualifying pre-assigned variant row was found in the governing SupplementaryTables or Parsons supplementary table.
Still missing
  • No c.918T>C, p.Asp306=, or p.D306= entry found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in HUMU-40-1557-s001.xlsx.txt.
  • PMID:16683254 reports one family but does not provide unaffected/control counts needed for a case-control OR, p-value, or 95% CI.
  • literature_pass.json contains no ai_classified_papers entries.
Sources
PM3 VCEPNot assessed: one family observation lacks the required same-gene pathogenic variant, phase, Fanconi Anemia phenotype, and PM3 point-bearing proband data. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 rule requires a patient with a phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and a co-occurrent variant in the same gene, with PM3 strength assigned from Table 6 points. The case evidence identifies c.918T>C/p.(D306=) in one family in PMID:16683254, but reports no phase, pathogenic or likely pathogenic variant in the same patient, affected-proband observations meeting the Fanconi Anemia phenotype definition, chromosome-breakage result, or PM3 point-bearing observation. Therefore PM3 cannot be assessed. The governing Specifications_V1.2_2024-11-18.docx file was searched for c.918T>C, p.Asp306=, and p.D306=; no variant-specific PM3 entry was found.

VCEP rule
Apply for patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia (FA), and co-occurrent variants in the same gene. Phenotype is considered consistent with BRCA1- or BRCA2-related FA if: (i) Increased chromosome breakage (DEB, MMC, or spontaneous) and at least one clinical feature indicative of BRCA1/2-related FA, categorized under: physical features, pathology and laboratory findings, cancer diagnosis ≤5yr. (ii) Result unknown for chromosome breakage, and at least two clinical features indicative of BRCA1/2-related FA under at least two of the three categories: physical features, pathology and laboratory findings, cancer diagnosis ≤5yr. See Appendix H Co-occurrent P or LP variant should be assigned classification using VCEP specifications. Variant under assessment must be sufficiently rare (not meeting a benign population evidence code). See Table 6 for approach to assign points per proband, and final PM3 code assignment based on the sum of PM3-related points.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2, PM3 rule: requires a patient with a phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and co-occurrent variants in the same gene; the variant under assessment must be sufficiently rare and PM3 is assigned from Table 6 points.
  • Table 6, PM3-related points: the qualifying observations are P or LP in trans or homozygote, or phase unknown, in a patient whose phenotype is consistent with BRCA1- or BRCA2-related Fanconi Anemia; final PM3 assignment is based on summed points.
  • PMID:16683254, Table 3, BRCA2 amplicon 10-1: c.918T>C/p.(D306=) was reported as a synonymous variant in 1 family with effect code B; the extracted finding provides no phase, co-occurrent pathogenic variant, or Fanconi Anemia phenotype data.
Still missing
  • No phase information (in trans, homozygous, or phase unknown) is available for the reported family observation.
  • No co-occurrent same-gene pathogenic or likely pathogenic variant is documented for the affected proband.
  • No chromosome-breakage result or sufficient Fanconi Anemia clinical phenotype is documented to satisfy the VCEP definition.
  • Specifications_V1.2_2024-11-18.docx was searched for c.918T>C, p.Asp306=, and p.D306=; no variant-specific PM3 entry was found.
Sources
PP1 VCEPNot assessed: the variant was observed in one family, but no quantitative segregation likelihood ratio or affected-family-member data is reported for the PP1 thresholds. Details ▾Hide ▴
Reasoning

The VCEP requires co-segregation in multiple affected family members measured by a quantitative co-segregation method and assigns PP1 strength from a Bayes-score likelihood ratio. The exact-variant publication reports c.918T>C/p.(D306=) in one family but provides no segregation data or quantitative LR. The governing SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, and HUMU-40-1557-s001.xlsx files were searched for c.918T>C, p.Asp306=, and p.D306=; no exact variant entry was found in those files.

VCEP rule
Co-segregation with disease in multiple affected family members See Appendix I Apply weight as per Bayes Score: PP1 - LR ≥2.08:1 PP1_Moderate – LR≥4.3:1 PP1_Strong – LR≥18.7:1 PP1_Very Strong – LR≥350:1
Evidence considered
  • ENIGMA Specifications v1.2, PP1_VariableWeight: co-segregation with disease in multiple affected family members, measured by a quantitative method, with PP1 Supporting at LR ≥2.08:1, Moderate at LR ≥4.3:1, Strong at LR ≥18.7:1, and Very Strong at LR ≥350:1.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1: c.918T>C, synonymous, observed in 1 family, effect B; the paper provides no variant-specific segregation result or quantitative segregation LR.
Still missing
  • No quantitative co-segregation likelihood ratio or pedigree-level affected-member genotype data is available for PP1.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in HUMU-40-1557-s001.xlsx.
Sources
PP4 VCEPNot assessed: no variant-specific combined clinical LR was found, so the ENIGMA PP4 thresholds beginning at LR ≥2.08:1 cannot be evaluated. Details ▾Hide ▴
Reasoning

The ENIGMA rule permits PP4 only for combined multifactorial clinical likelihood toward pathogenicity and requires LR ≥2.08:1 for supporting, ≥4.3:1 for moderate, ≥18.7:1 for strong, or ≥350:1 for very strong. No exact NM_000059.4:c.918T>C entry was found in PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt, and the available literature does not provide a combined clinical LR for this variant. PP4 is therefore not assessed.

VCEP rule
Breast cancer is very common and has a high degree of genetic heterogeneity (caused by pathogenic variants in numerous genes). Use ONLY to capture combined LR towards pathogenicity, based on multifactorial likelihood clinical data. ... PP4 - LR ≥2.08:1 ... PP4_Moderate – LR≥4.3:1 ... PP4_Strong – LR≥18.7:1 ... PP4_Very Strong – LR≥350:1
Evidence considered
  • ENIGMA BRCA2 specification PP4 rule: use only combined LR toward pathogenicity from multifactorial likelihood clinical data; supporting requires LR ≥2.08:1, moderate ≥4.3:1, strong ≥18.7:1, and very strong ≥350:1.
  • PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt was searched for c.918T>C, p.Asp306=, and p.D306=; no exact BRCA2 row was found.
  • The reviewed Li, Easton, and Parsons materials provide methodology or other variant rows, not a combined clinical LR for this variant.
Still missing
  • No c.918T>C, p.Asp306=, or p.D306= entry found in PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt.
  • No variant-specific combined clinical LR was available from the reviewed Li, Easton, or Parsons materials.
Sources
BS2 VCEPNot assessed: no qualifying healthy-adult zygosity, age/follow-up, co-occurrence, or Fanconi Anemia phenotype evidence is available for BS2 point assignment. Details ▾Hide ▴
Reasoning

The ENIGMA BS2 rule requires observation in a healthy adult in the relevant zygosity state, with the criterion's point assignment based on qualifying clinical or research-cohort observations and absence of Fanconi Anemia features. The available evidence documents no homozygotes and provides no qualifying healthy-adult heterozygote, trans co-occurrence, age/follow-up, or Fanconi Anemia assessment for this variant. BS2 cannot be evaluated from the available evidence.

VCEP rule
Applied in absence of features of recessive disease, namely Fanconi Anemia phenotype. See Specifications Table 8 for additional stipulations, and approach to assign points per proband, and final BS2 code assignment based on the sum of BS2-related points. See Appendix H for additional details.
Evidence considered
  • gnomAD v2.1 non-cancer exomes report 0 homozygotes; gnomAD v3.1 non-cancer genomes report 0 homozygotes. These population observations cannot be converted into BS2 points under the ENIGMA stipulation excluding frequency-code data from BS2.
  • Specifications_V1.2_2024-11-18.docx, Table 1 BS2: the criterion is applied in the absence of Fanconi Anemia features and requires point assignment per proband using Table 8.
  • Appendices_V1.2_2024-11-18.docx, Appendix H: BS2 points are assigned for trans co-occurrence with a P/LP variant or homozygosity in a presumed Fanconi-Anemia-unaffected patient, with age/cancer-diagnosis criteria; homozygote observations from gnomAD are not to be used for frequency-based codes.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= row was found in HUMU-40-1557-s001.xlsx.txt.
  • The case evidence has no qualifying healthy-adult clinical or research-cohort observation with the age/follow-up and zygosity information required for BS2 point assignment.
Sources
BS3 VCEPNot assessed: no ENIGMA Table 9 entry or variant-specific protein/combined mRNA-protein assay demonstrates no damaging effect on protein function. Details ▾Hide ▴
Reasoning

BS3 cannot be assessed because the ENIGMA BRCA2 Table 9 curated functional-assay file contains no entry for c.918T>C, p.Asp306=, or p.D306=, and the available exact-variant publication reports only a synonymous observation without a protein-function or combined mRNA/protein assay. The VCEP requires a well-established functional study showing no damaging effect on protein function through protein-only or combined mRNA-and-protein measurement; no such calibrated assay result is available.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function. Assay measures effect via protein only OR mRNA and protein combined.
Evidence considered
  • ENIGMA Specifications Table 9, searched by c.918T>C, p.Asp306=, and p.D306=: no matching curated functional-assay row was present.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, and HUMU-40-1557-s001.xlsx were searched under all three variant notations; no variant-specific PS3/BS3 functional result was found.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1, row c.918T4C: synonymous, observed in 1 family, coded B; the paper provides no functional assay result for this variant.
Still missing
  • No c.918T>C, p.Asp306=, or p.D306= entry found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in HUMU-40-1557-s001.xlsx.txt.
  • No c.918T>C, p.Asp306=, or p.D306= entry found in Specifications_Table9_V1.2_2024-11-18.xlsx.txt.
  • A calibrated protein-only or combined mRNA/protein functional assay with validated controls and variant-specific results is unavailable in the reviewed evidence.
Sources
BS4 VCEPNot assessed: the variant was observed in one family, but no quantitative non-segregation likelihood ratio or affected-family-member genotype data is reported for BS4 thresholds. Details ▾Hide ▴
Reasoning

The VCEP requires lack of segregation in affected family members measured by a quantitative co-segregation method and assigns BS4 strength from a Bayes-score likelihood ratio. The exact-variant publication reports c.918T>C/p.(D306=) in one family but provides no non-segregation result or quantitative LR. The governing SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, and HUMU-40-1557-s001.xlsx files were searched for c.918T>C, p.Asp306=, and p.D306=; no exact variant entry was found in those files.

VCEP rule
Lack of segregation in affected members of a family. See Appendix I. Apply weight as per Bayes Score: BS4_Supporting - LR ≤0.48 to &gt;0.23:1 BS4_Moderate - LR ≤0.23:1 BS4 - LR ≤0.05:1 BS4_Very strong – LR ≤0.00285:1
Evidence considered
  • ENIGMA Specifications v1.2, BS4_VariableWeight: lack of segregation in affected family members, measured by a quantitative method, with BS4 Supporting at LR ≤0.48 to >0.23:1, Moderate at LR ≤0.23:1, Strong at LR ≤0.05:1, and Very Strong at LR ≤0.00285:1.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1: c.918T>C, synonymous, observed in 1 family, effect B; the paper provides no variant-specific non-segregation result or quantitative BS4 LR.
Still missing
  • No quantitative non-segregation likelihood ratio or pedigree-level affected-member genotype data is available for BS4.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in HUMU-40-1557-s001.xlsx.
Sources
BP5 VCEPNot assessed: no combined clinical LR was available for comparison with the BP5 supporting operator LR ≤0.48 to >0.23. Details ▾Hide ▴
Reasoning

The ENIGMA rule permits BP5 only for a combined multifactorial clinical LR against pathogenicity. Its operators are LR ≤0.48 to >0.23 for supporting, LR ≤0.23 for moderate, LR ≤0.05 for strong, and LR ≤0.00285 for very strong. No exact variant row was found in PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt, and no combined clinical LR for NM_000059.4:c.918T>C was available; BP5 is not assessed.

VCEP rule
Use ONLY to capture combined LR against pathogenicity, based on multifactorial likelihood clinical data. ... BP5_VeryStrong – LR ≤0.00285:1 ... BP5_Strong - LR ≤0.05:1 ... BP5_Moderate - LR ≤0.23:1 ... BP5 - LR ≤0.48 to >0.23:1
Evidence considered
  • ENIGMA BRCA2 specification BP5 rule: use only combined LR against pathogenicity from multifactorial likelihood clinical data; supporting is LR ≤0.48 to >0.23, moderate LR ≤0.23, strong LR ≤0.05, and very strong LR ≤0.00285.
  • The BP5 supporting comparison would be written as LR ≤0.48, but no variant-specific LR exists to substitute into the inequality.
  • PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt was searched for c.918T>C, p.Asp306=, and p.D306=; no exact BRCA2 row was found.
Still missing
  • No c.918T>C, p.Asp306=, or p.D306= entry found in PMID_31853058_BRCA2_clinical_history_LR.xlsx.txt.
  • No variant-specific combined multifactorial clinical LR was available for BP5 evaluation.
Sources
Not applicable · 13· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: the exon-10 synonymous substitution (T>C at coding position 918; Asp306=) is not one of the VCEP-defined null variant classes eligible for PVS1. Details ▾Hide ▴
Reasoning

PVS1 is not applicable. NM_000059.4:c.918T>C, encoding NP_000050.3:p.(Asp306=) (p.(D306=)), is a synonymous substitution in exon 10, not a nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion null variant. The ENIGMA BRCA2 PVS1 rule is restricted to those null variant classes, and Table 4 provides exon-10 PVS1 decisions for PTC, splice-site, deletion, and duplication variants rather than synonymous substitutions. SpliceAI max delta is 0.006, but the VCEP PVS1 rule does not make a synonymous substitution eligible on the basis of this prediction.

VCEP rule
Null variant in a gene where loss of function is a known mechanism of disease.
Evidence considered
  • Variant Validator and case facts: NM_000059.4:c.918T>C is an exonic synonymous substitution in exon 10 with NP_000050.3:p.(Asp306=) / p.(D306=).
  • ENIGMA Specifications v1.2, PVS1 rule: the eligible null variant classes are nonsense, frameshift, canonical donor/acceptor +/-1,2 splice-site, initiation-codon, and single- or multi-exon deletion variants in a gene where loss of function is a known disease mechanism.
  • ENIGMA Specifications Table 4, BRCA2 E10 row: exon-10 PVS1 entries concern PTC, splice-site, deletion, and duplication variants; no synonymous-substitution entry applies to c.918T>C.
  • SpliceAI result for c.918T>C: maximum delta score 0.006; this does not convert the synonymous substitution into a PVS1-eligible null variant under the governing PVS1 rule.
  • Houdayer et al. 2012, PMID:22505045, was searched in the governing VCEP-listed paper and no c.918T>C, p.Asp306=, or p.D306= entry was found.
  • van der Hout et al. 2006, PMID:16683254, Table 3, BRCA2 amplicon 10-1: c.918T>C is listed as synonymous and observed in 1 family, with paper code B (unknown effect); no truncating or splice consequence is reported.
Still missing
  • No direct c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, Specifications_Table4_V1.2_2024-11-18.xlsx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt; this is a search result, not evidence that the variant lacks evidence.
Sources
PS1 N/ANot applicable: this synonymous variant has SpliceAI maximum delta 0.006 and meets neither the VCEP's missense nor matching-splicing PS1 route. Details ▾Hide ▴
Reasoning

The variant is synonymous, NP_000050.3:p.(Asp306=), rather than a missense substitution. SpliceAI maximum delta is 0.006, below the VCEP's 0.1 no-impact boundary, and no matching pathogenic splice event is available. The VCEP restricts PS1 to the same missense substitution or the same predicted splicing impact as a previously classified pathogenic or likely pathogenic variant; neither route applies here.

VCEP rule
Apply PS1, for predicted missense substitutions, where a previously classified pathogenic variant is considered to act via protein change (no confirmed or predicted effect on mRNA splicing (SpliceAI≤0.1)). ... Apply PS1_Moderate, for predicted missense substitutions, where previously established likely pathogenic variant is considered to act via protein change (no confirmed or predicted effect on mRNA splicing (SpliceAI≤0.1)). ... Apply PS1_Variable Weight, for exonic and intronic variants with same predicted impact on splicing, as a previously classified (likely) pathogenic variant.
Evidence considered
  • Case normalization identifies NM_000059.4:c.918T>C as the synonymous variant NP_000050.3:p.(Asp306=) / p.(D306=).
  • SpliceAI maximum delta score is 0.006, which is below the VCEP's no-predicted-splicing boundary of 0.1.
  • The VCEP PS1 rule requires either the same missense substitution as a previously classified pathogenic or likely pathogenic variant or the same predicted splicing impact as such a variant; the synonymous variant has neither qualifying route.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
PS2 VCEPNot applicable: the ENIGMA BRCA2 specification explicitly prohibits PS2 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly says PS2 is not to be used because BRCA1/2-related cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated.

VCEP rule
De novo (paternity confirmed) in a patient with the disease and no family history. ... Do not use BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • ENIGMA Specifications v1.2, PS2 entry: de novo occurrences are designated Do not use because BRCA1/2-related cancers occur relatively commonly and their predictive capacity is uncalibrated.
Sources
PM1 VCEPNot applicable: the VCEP marks PM1 not for use, and residue 306 lies outside its defined BRCA2 domains 10-40 and 2481-3186. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PM1 as not for use and directs this domain/hotspot information into PP3/BP4. The VCEP-defined BRCA2 clinically important domains are PALB2 binding residues 10-40 and DNA binding residues 2481-3186; residue 306 lies outside both. The case vcep_materials domain_tables key is empty, so no additional authoritative domain-table entry exists for this gene in the case materials.

VCEP rule
Located in a mutational hot spot and/or critical and well-established functional domain. ... Do not use Considered as component of bioinformatic analysis (PP3/BP4).
Evidence considered
  • The VCEP PM1 entry states: Do not use; PM1 is considered as a component of bioinformatic analysis under PP3/BP4.
  • The VCEP's BRCA2 functional-domain definition is PALB2 binding domain amino acids 10-40 and DNA binding amino acids 2481-3186; amino acid 306 is outside both domains.
  • vcep_materials.json has domain_tables: {}, so there is no additional gene-specific domain-table entry to evaluate.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
PM4 VCEPNot applicable: Asp306= causes no protein-length change, and the ENIGMA BRCA2 specification explicitly states that PM4 is not used. Details ▾Hide ▴
Reasoning

PM4 is not applicable under the BRCA2 ENIGMA VCEP specification. The variant is synonymous and produces no protein-length change, and the specification explicitly states that PM4 is not used; therefore no in-frame deletion/insertion or stop-loss assessment can apply.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants. ... Do not use
Evidence considered
  • Variant consequence: c.918T>C is synonymous, p.(Asp306=), so the encoded protein length is unchanged.
  • ENIGMA Specifications v1.2, PM4 row: PM4 is defined for protein-length changes from in-frame deletions/insertions in a non-repeat region or stop-loss variants, and the specification says 'Do not use' and that it is considered as part of bioinformatic analysis.
Still missing
  • No direct c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, Specifications_Table4_V1.2_2024-11-18.xlsx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt; this is a search result, not evidence that the variant lacks evidence.
Sources
PM5 N/ANot applicable: c.918T>C is synonymous, while the VCEP excludes missense PM5 and reserves its PM5 route for PVS1 protein-termination variants. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks the missense PM5 criterion as not for use and directs the relevant information into PP3/BP4. This variant is synonymous, not a missense change. The VCEP's separate PM5 (PTC) route is limited to protein-termination-codon variants annotated with PVS1, which does not describe c.918T>C.

VCEP rule
Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Do not use Considered as component of bioinformatic analysis (PP3/BP4).
Evidence considered
  • The VCEP PM5 entry states: Do not use; PM5 is considered as a component of bioinformatic analysis under PP3/BP4.
  • The separate PM5 (PTC) rule applies only to protein termination codon variants annotated as PVS1 and uses exon-specific Table 4 weights; this case variant is synonymous in exon 10.
  • Specifications Table 4 contains the BRCA2 exon 10 PTC row, but no exact c.918T>C, p.Asp306=, or p.D306= variant entry.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
PM6 VCEPNot applicable: the ENIGMA BRCA2 specification explicitly prohibits PM6 because de novo predictive capacity is not calibrated for common BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly says PM6 is not to be used because BRCA1/2-related cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated.

VCEP rule
Confirmed de novo without confirmation of paternity and maternity. ... Do not use BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • ENIGMA Specifications v1.2, PM6 entry: confirmed de novo without paternity and maternity confirmation is designated Do not use because de novo predictive capacity is uncalibrated.
Sources
PP2 VCEPNot applicable: the VCEP excludes PP2 because missense variants are not a common BRCA2 pathogenic mechanism, and this variant is synonymous. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PP2 as not for use because missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2. The assessed variant is also synonymous rather than missense.

VCEP rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. ... Do not use High frequency of benign missense variants.
Evidence considered
  • The VCEP PP2 entry states: Do not use; high frequency of benign missense variants.
  • The case consequence is synonymous, so it does not meet the missense-variant type named by PP2.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
PP5 VCEPNot applicable: the ENIGMA BRCA2 specification explicitly says PP5 is not to be used. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly states Do not use for PP5. ClinVar's expert-panel Likely benign classification and individual submission records therefore do not create PP5 evidence under this VCEP.

VCEP rule
Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation. ... Do not use
Evidence considered
  • ENIGMA BRCA2 specification PP5 entry: reputable-source pathogenic reports are followed by the explicit instruction Do not use.
  • ClinVar reports this variant as Likely benign with expert-panel review; this is not used to apply PP5 because the VCEP prohibits the criterion.
Sources
BP2 VCEPNot applicable: the ENIGMA BRCA2 specification says BP2 is not to be used and applies it only in the context of BS2. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly states that BP2 is not to be used and is applied only in the context of BS2. Accordingly, BP2 is not applicable for this adjudication regardless of whether cis or trans co-occurrence evidence is available.

VCEP rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder, or observed in cis with a pathogenic variant in any inheritance pattern Do not use Applied only in the context of BS2.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2, BP2 entry: observed in trans with a pathogenic variant for a fully penetrant dominant disorder or observed in cis with a pathogenic variant, followed by the VCEP instruction "Do not use" and "Applied only in the context of BS2."
Sources
BP3 VCEPNot applicable: c.918T>C is a synonymous p.Asp306= substitution, not an in-frame insertion/deletion, and the VCEP explicitly says BP3 is not used. Details ▾Hide ▴
Reasoning

BP3 is not applicable under the ClinGen ENIGMA BRCA2 VCEP specification. The variant is NM_000059.4:c.918T>C, a synonymous substitution producing NP_000050.3:p.(Asp306=) / p.(D306=), with no in-frame insertion or deletion and no protein-length change. The governing specification limits BP3 to in-frame deletions/insertions in a repetitive region without a known function and explicitly says not to use it; the appendix states that this evidence is captured by bioinformatic tool prediction and domain analysis.

VCEP rule
In-frame deletions/insertions in a repetitive region without a known function ... Do not use ... Captured by bioinformatic tool prediction, and domain analysis. ... See Appendix J.
Evidence considered
  • Variant consequence: NM_000059.4:c.918T>C is synonymous and produces NP_000050.3:p.(Asp306=) / p.(D306=); it is not an in-frame insertion or deletion and does not change protein length.
  • ClinGen ENIGMA BRCA2 Specifications v1.2, BP3 row: 'In-frame deletions/insertions in a repetitive region without a known function'; the same row says 'Do not use' and 'Captured by bioinformatic tool prediction, and domain analysis. See Appendix J.'
  • ClinGen ENIGMA BRCA2 Appendices v1.2, BP3 entry: 'N/A. Captured by bioinformatic tool prediction, and domain analysis.'
Still missing
  • No direct c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, Specifications_Table4_V1.2_2024-11-18.xlsx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt; this is a search result, not evidence that the variant lacks evidence.
Sources
BP4 N/ANot applicable: BP4's silent-variant path is restricted to clinically important domains, and p.Asp306= lies outside aa 10-40 and aa 2481-3186. Details ▾Hide ▴
Reasoning

The variant is a synonymous substitution at amino acid 306. Under the ENIGMA BRCA2 rule, the silent-variant BP4 path applies only to a silent variant inside a potentially clinically important functional domain. The specified BRCA2 domains are the PALB2-binding domain at aa 10-40 and the DNA-binding domain at aa 2481-3186; aa306 is outside both. BP4 is therefore not applicable, regardless of the available SpliceAI score.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1).
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2 restricts the silent-variant BP4 path to variants inside a potentially clinically important functional domain.
  • The same specification defines the BRCA2 domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; p.Asp306= is at aa306 and is outside both domains.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP7 N/ANot applicable: BP7's silent-variant path requires a clinically important domain location, but p.Asp306= lies outside both specified BRCA2 domains. Details ▾Hide ▴
Reasoning

The variant is synonymous at amino acid 306. The ENIGMA BRCA2 BP7 application rule for silent variants is limited to a silent variant inside a potentially clinically important functional domain, if BP4 is met. The specified BRCA2 domains are aa 10-40 and aa 2481-3186, so p.Asp306= lies outside the permitted BP7 silent-variant scope. BP7 is not applicable; the no-splice prediction cannot extend the criterion beyond its governing scope.

VCEP rule
Apply BP7 for Silent variant inside a (potentially) clinically important functional domain, IF BP4 met.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2: BP7 applies to a silent variant inside a potentially clinically important functional domain only if BP4 is met.
  • The specification defines the BRCA2 domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; p.Asp306= is outside both domains.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Identifiers

Gene
BRCA2
Transcript
NM_000059.4
Coding (HGVS c.)
NM_000059.4:c.918T>C
Protein (HGVS p.)
NP_000050.3:p.(Asp306=)
GRCh38
chr13:32332396 T>C
GRCh37
chr13:32906533 T>C
Location and type
Exon 10 · synonymous
ClinVar
184704

Gene diagram

Every interpreted variant in BRCA2, mapped onto the exon structure of NM_000059.4. Select a row to find it on the plot.

BRCA2NM_000059.4
Fetching transcript structure from UCSC…
gnomAD v4.1 15 / 1,591,562 alleles AF 9.42e-06 · 0 homozygotes · FAF 4.65e-05
gnomAD v2.1 6 / 235,344 alleles AF 2.55e-05 · 0 homozygotes · FAF 6.4e-05
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 9.4e-06 · 15 / 1,591,562 alleles · 0 hom · FAF 4.7e-05
Admixed American6 / 55,826 0.00011
European (non-Finnish)9 / 1,169,900 7.7e-06
0 alternate alleles recorded in 8 other groups: Remaining individuals, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 2.5e-05 · 6 / 235,344 alleles · 0 hom · FAF 6.4e-05
Admixed American5 / 30,540 0.00016
European (non-Finnish)1 / 109,248 9.2e-06
0 alternate alleles recorded in 6 other groups: African/African American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 9.4247e-06; MAF= 0.00094%, 15/1591562 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 0.000107477; MAF= 0.01075%, 6/55826 alleles, homozygotes = 0); grpmax FAF= 4.651e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 2.54946e-05; MAF= 0.00255%, 6/235344 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 0.00016372; MAF= 0.01637%, 5/30540 alleles, homozygotes = 0); grpmax FAF= 6.404e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +287 bp
0.001
SpliceAI acceptor gainat -124 bp
0.001
SpliceAI donor lossat -93 bp
0.001
SpliceAI donor gainat +48 bp
0.006
Pangolin splice lossmagnitude shown
-0.003
Pangolin splice gain
0.034

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 VCEPNot met: SpliceAI maximum delta 0.006 is below the ENIGMA PP3 threshold of ≥0.2 for predicted splicing in silent variants. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_000059.4:c.918T>C; p.Asp306=). The governing ENIGMA rule permits PP3 for predicted splicing in silent variants and requires SpliceAI ≥0.2. The case-specific SpliceAI maximum delta score is 0.006 (DS_DG 0.006; all other delta scores 0.001), below the VCEP threshold; therefore PP3 is not met. No exact variant entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2: PP3 applies to predicted splicing for silent variants when SpliceAI ≥0.2.
  • SpliceAI Lookup for NM_000059.4:c.918T>C: DS_AG=0.001, DS_AL=0.001, DS_DG=0.006, DS_DL=0.001; maximum delta score=0.006.
  • van der Hout et al. 2006, Table 3, BRCA2 amplicon 10-1: c.918T>C is reported as a synonymous variant observed in one family, confirming the silent-variant scope.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP4 N/ANot applicable: BP4's silent-variant path is restricted to clinically important domains, and p.Asp306= lies outside aa 10-40 and aa 2481-3186. Details ▾Hide ▴
Reasoning

The variant is a synonymous substitution at amino acid 306. Under the ENIGMA BRCA2 rule, the silent-variant BP4 path applies only to a silent variant inside a potentially clinically important functional domain. The specified BRCA2 domains are the PALB2-binding domain at aa 10-40 and the DNA-binding domain at aa 2481-3186; aa306 is outside both. BP4 is therefore not applicable, regardless of the available SpliceAI score.

VCEP rule
Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1).
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2 restricts the silent-variant BP4 path to variants inside a potentially clinically important functional domain.
  • The same specification defines the BRCA2 domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; p.Asp306= is at aa306 and is outside both domains.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP7 N/ANot applicable: BP7's silent-variant path requires a clinically important domain location, but p.Asp306= lies outside both specified BRCA2 domains. Details ▾Hide ▴
Reasoning

The variant is synonymous at amino acid 306. The ENIGMA BRCA2 BP7 application rule for silent variants is limited to a silent variant inside a potentially clinically important functional domain, if BP4 is met. The specified BRCA2 domains are aa 10-40 and aa 2481-3186, so p.Asp306= lies outside the permitted BP7 silent-variant scope. BP7 is not applicable; the no-splice prediction cannot extend the criterion beyond its governing scope.

VCEP rule
Apply BP7 for Silent variant inside a (potentially) clinically important functional domain, IF BP4 met.
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2: BP7 applies to a silent variant inside a potentially clinically important functional domain only if BP4 is met.
  • The specification defines the BRCA2 domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; p.Asp306= is outside both domains.
Still missing
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.918T>C, p.Asp306=, or p.D306= entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).

9 paper records listed. 1 cited in the classification.

Cited in the classification

  • A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
    van der Hout AH et al. · 2006 Jul
    The paper explicitly reports BRCA2 c.918T>C in amplicon 10-1 as a synonymous variant, corresponding to NP_000050.3:p.(D306=). It was observed in 1 family during BRCA1/BRCA2 mutation screening and was classified in the table as effect 'B,' meaning unknown in the paper's coding system; no functional, segregation, or population-frequency data for this variant are provided.
    → BP1 · strong Names this variant
    PMID 16683254 ↗
    Source detail
    10-1 c.918T4C Synonymous 1 B

    Location Table 3, Unclassified Variants in BRCA1 and BRCA2, BRCA2 amplicon 10-1

    Context Semiautomated denaturing gradient gel electrophoresis (DGGE) mutation screening of BRCA1 and BRCA2 in Dutch cancer-clinic families, followed by sequence analysis of aberrant fragments.

Other recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    No paper-specific finding is recorded.
    PMID 26467025 ↗
  • Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
    No paper-specific finding is recorded.
    PMID 31672839 ↗
  • The emerging landscape of breast cancer susceptibility.
    Stratton MR et al. · 2008
    No paper-specific finding is recorded.
    PMID 18163131 ↗
  • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301425 ↗
  • ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    No paper-specific finding is recorded.
    PMID 23788249 ↗
  • American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
    No paper-specific finding is recorded.
    PMID 26324357 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 9.4247e-06; MAF= 0.00094%, 15/1591562 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 0.000107477; MAF= 0.01075%, 6/55826 alleles, homozygotes = 0); grpmax FAF= 4.651e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 2.54946e-05; MAF= 0.00255%, 6/235344 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 0.00016372; MAF= 0.01637%, 5/30540 alleles, homozygotes = 0); grpmax FAF= 6.404e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Likely benign (7 clinical laboratories) and as likely benign (1 clinical laboratory) and as Likely Benign (1 clinical laboratory) and as Likely benign by Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) (expert panel). (ClinVarID = 184704)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).

Functional

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.